News on research and diagnostic development for pathogenic diseases.
The FDA last week also reissued an EUA for a PCR-based SARS-CoV-2 test from Quest Diagnostics to permit its use with pooled samples.
The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, is designed to construct a metagenomic sequencing library directly from clinical samples.
The wastewater analytics firm will work with the two government agencies to analyze samples from treatment plants across the US for SARS-CoV-2 viral elements.
The RT-PCR-based test was first authorized earlier this year for the detection of SARS-CoV-2 nucleic acid in specimens collected by a healthcare provider.
A team led by researchers at University College London studied mutations in almost 47,000 viral genomes collected from patients worldwide.
